Peptides
Pramlintide (Symlin)
Also called Symlin
Symlin helps people using mealtime insulin control the rise in blood sugar after food. It may also help with fullness and weight, but its meal-by-meal use and insulin adjustments make it very different from a weekly weight-loss injection.
Dosage & duration
US label context for adults already using mealtime insulin.
Type 1 diabetes
Product label- Dose
- 15 mcg starting dose; titrated toward 30–60 mcg
- How often
- Immediately before major meals, under the skin
- How long
- Ongoing treatment
Gradual increases require tolerability assessment and a coordinated insulin plan.
Sources: 1
Type 2 diabetes
Product label- Dose
- 60 mcg starting dose; may increase to 120 mcg
- How often
- Immediately before major meals, under the skin
- How long
- Ongoing treatment
Label defines major meals as at least 250 calories or 30 g carbohydrate.
Sources: 1
These are micrograms, not milligrams. The label’s insulin changes and monitoring are integral to treatment.
Symlin and mealtimes
An after-meal glucose tool with extra coordination
-
After-meal blood sugar
Symlin helps limit the rise after food in people using mealtime insulin.
-
Meals shape the routine
Treatment is linked to qualifying meals rather than a weekly appetite schedule.
-
Insulin needs a plan
The combination can cause severe low blood sugar and requires clinician-led insulin adjustment.
What people use it for
Pramlintide replaces some actions of amylin, a hormone normally released with insulin. It slows stomach emptying and helps limit the after-meal glucose rise. This is add-on diabetes care, not a substitute for insulin.
Why the insulin plan matters
Symlin and mealtime insulin can cause severe low blood sugar together. The label calls for an initial 50% mealtime-insulin reduction, frequent glucose checks and subsequent clinician-led adjustment. Do not add it to an unchanged insulin routine based on a plot.
Meals, not a weekly cycle
The injection is linked to major meals rather than taken as a weekly appetite shot. Nausea and changes in food intake affect how well it fits daily life. Confirmed gastroparesis and hypoglycemia unawareness are contraindications.
Model details: Pramlintide (Symlin) · estimated
How to read this estimate
Estimated from study endpoints; the curve between measurements is reconstructed. Compare amounts and timing in mg.
A concentration estimate reconstructed from the stated source dose and timing.
Assumptions, calculation and sources
Symlin pramlintide acetate solution; dose stated as pramlintide mass, not acetate-salt mass.. subcutaneous. Healthy individuals after abdominal/thigh SC injection..
pramlintide: estimated concentration in plasma (nmol/L).
Symlin label Table5: Tmax21minutes=.35h; half-life48minutes=.8h.
- Calibration dose
- 0.12 mg
- Reported calibration peak
- 0.147 nmol/L
- Peak timing used
- 0.35 hours
- Terminal half-life used
- 0.8 hours
- Reconstructed absorption rate
- 6.718556 /hour
- Observed extravascular concentrations already contain bioavailability; do not multiply by legacy F or add an independently assumed F.
- Dose scaling and repeated-dose superposition use fixed parameters; the example dose does not calibrate the curve.
- No added30–40%bioavailability multiplier; observed SC endpoint already contains it.
- One-compartment reconstruction overestimates AUC by15.17%, so it is an endpoint approximation.
- Fast peak needs sub-hour sampling to avoid an apparently tiny/missing peak on coarse weekly grids.
- Symlin US label,12.3 Table5 and11 Description
120mcg:147pmol/L peak,21min Tmax,48min half-life,AUCinf11970pmol*min/L. Native pramlintide molecular weight3949.4g/mol; no conversion needed for recommended molar output.
Estimate pramlintide-source-estimate-2026-10 · version 1
Common questions
Does Symlin replace insulin?
No. It is an add-on for eligible people using mealtime insulin.
Is this the same as cagrilintide?
No. Both relate to amylin, but their products, timing and evidence differ.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main goal
- Used alongside mealtime insulin.
- Schedule
- This is not a weekly GLP-1 product.
- Main risk
- Insulin coordination is essential.
- 1. Symlin US prescribing information
Type 1 and type 2 doses differ; severe hypoglycemia boxed warning with insulin. Label requires initial mealtime-insulin reduction and monitoring.
- 2. University of Washington — Symlin patient education
Patient questions: after-meal glucose and possible weight loss; does not replace current prescribing information.
- 3. Symlin US label,12.3 Table5 and11 Description
120mcg:147pmol/L peak,21min Tmax,48min half-life,AUCinf11970pmol*min/L. Native pramlintide molecular weight3949.4g/mol; no conversion needed for recommended molar output.
Related compounds and examples
Related compounds
Cagrilintide
Cagrilintide explained: appetite, trial doses, nausea and the difference between standalone use and CagriSema.
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.
Semaglutide Oral (Rybelsus)
Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.